Antimicrobial Susceptibility Testing Update - SWACM

More documents

Recommendations

Info

Status of New Breakpoint ConcentrationsAvailable on Commercial AST Systems 1<strong>Antimicrobial</strong>AztreonamCefazolinCefotaximeCeftriaxoneCeftazidimeMicroScanx-xxxPhoenixx---xSensititrexxxxxVitek2x-xxxEtestxxxxxDoripenemErtapenemImipenemMeropenem-xxx--xxxxxxx-xxxxxx1 For some, only available on specific panel types (e.g., ESBL)
Some concerns about the newbreakpoints…..(1)Cephalosporins and aztreonambreakpointsEliminating ESBL confirmatory test will resultin reporting some cephalosporins as “S” forsome ESBL positive strainsClinical data limited for using cephalosporinsto treat ESBL producers when MICs are lowNo change for cefepime quite controversialCefazolinbreakpoints not appropriate for oralcephalosporins for UTI
Page 1 and 2:
Antimicrobial SusceptibilityTesting
Page 3 and 4: CLSI AST StandardsAugust 2010M100-S
Page 5: Ceftriaxone Prescribing Information
Page 8 and 9: Enterobacteriaceae - Cephalosporins
Page 10 and 11: Table 2A Enterobacteriaceae♦ Dosi
Page 12 and 13: Why did CLSI lower cephalosporin,az
Page 14 and 15: Old ParadigmEmergence of a new β-l
Page 16 and 17: www.eucast.org
Page 18 and 19: MEROPENEM MIC distribution exampleB
Page 20 and 21: PK-PD PD Goal (“Target(Target”)
Page 22 and 23: Factors that Affect PK-PDPDTarget A
Page 24 and 25: What PK-PD PD data were used torevi
Page 26 and 27: Probability of Target AttainmentImi
Page 28 and 29: ImipenemProbability ofTarget Attain
Page 30 and 31: Enterobacteriaceae% Capture of Carb
Page 32 and 33: Meropenem MIC DistributionsEnteroba
Page 34 and 35: Expected Results forCarbapenemase-P
Page 36 and 37: Cumulative Ceftriaxone MIC Distribu
Page 38 and 39: Ceftriaxone MIC DistributionC. freu
Page 40 and 41: E. coli, Klebsiella spp., Proteus m
Page 42 and 43: Expected Results forESBL-ProducersC
Page 44 and 45: Why was cefepime breakpoint notlowe
Page 46 and 47: Why did cephalothin get moved?As re
Page 48 and 49: What narrow-spectrum cephalosporin
Page 50 and 51: Brief CLSI and FDABreakpoint (BP) S
Page 52 and 53: Steps to ImplementingNew CLSI Cepha
Page 56 and 57: Some concerns about the newbreakpoi
Page 58 and 59: http://www.clsi.org/Content/Navigat
show all

Antimicrobial Susceptibility Testing Update - SWACM

Create successful ePaper yourself

Delete template?

Save as template?